Canaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Edward Nash maintains Pliant Therapeutics (NASDAQ:PLRX) with a Hold and lowers the price target from $4 to $3.
Canaccord Genuity analyst Edward Nash maintains Pliant Therapeutics (NASDAQ:PLRX) with a Hold and lowers the price target from $4 to $3.